• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl-phenylketones

Introduction to Filixic Acid ABA (CAS No. 38226-84-5) and Its Emerging Applications in Chemical Biology

Filixic Acid ABA, identified by the Chemical Abstracts Service registry number CAS No. 38226-84-5, is a naturally occurring compound that has garnered significant attention in the field of chemical biology due to its unique structural properties and bioactive potential. This compound, belonging to the saponin class, has been extensively studied for its pharmacological effects, particularly in modulating cellular signaling pathways and exhibiting anti-inflammatory, antioxidant, and anticancer properties. The increasing interest in Filixic Acid ABA stems from its ability to interact with various biological targets, making it a promising candidate for therapeutic development.

The structural complexity of Filixic Acid ABA contributes to its multifaceted biological activities. Its molecular framework consists of a triterpene aglycone moiety linked to a sugar moiety, which enhances its solubility and bioavailability. Recent studies have highlighted the compound's role in inhibiting the activity of enzymes involved in inflammation, such as lipoxygenase and cyclooxygenase. These findings align with the growing body of evidence suggesting that saponins can modulate immune responses by interacting with membrane receptors and intracellular signaling cascades.

In the realm of oncology, Filixic Acid ABA has demonstrated remarkable potential as an anticancer agent. Preclinical studies have revealed its ability to induce apoptosis in cancer cells by activating caspase-dependent pathways. Additionally, it has shown promise in suppressing tumor growth and metastasis by disrupting key signaling pathways such as PI3K/Akt and MAPK. The compound's ability to selectively target cancer cells while sparing healthy tissues makes it an attractive candidate for further clinical investigation.

Another area where Filixic Acid ABA has shown promise is in neuroprotection. Emerging research indicates that this compound can cross the blood-brain barrier and exert neuroprotective effects against oxidative stress-induced neuronal damage. Studies have demonstrated its ability to attenuate neuroinflammation and protect against neurodegenerative diseases such as Alzheimer's and Parkinson's. The mechanisms underlying these effects are believed to involve the modulation of microglial activation and the inhibition of pro-inflammatory cytokine production.

The anti-inflammatory properties of Filixic Acid ABA have also been explored in the context of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Research suggests that the compound can reduce inflammation by inhibiting nuclear factor kappa B (NF-κB) signaling, a key transcription factor involved in inflammatory responses. By targeting NF-κB, Filixic Acid ABA can effectively reduce the production of pro-inflammatory cytokines, thereby alleviating symptoms associated with these conditions.

Recent advancements in synthetic chemistry have enabled the development of novel derivatives of Filixic Acid ABA with enhanced bioactivity and improved pharmacokinetic profiles. These derivatives retain the core structural features responsible for their biological activity while incorporating modifications that enhance their stability, solubility, and target specificity. Such innovations are paving the way for more effective therapeutic strategies based on this promising natural product.

The growing body of evidence supporting the therapeutic potential of Filixic Acid ABA has prompted several pharmaceutical companies to initiate clinical trials evaluating its efficacy and safety in human populations. These trials aim to provide further insights into its mechanisms of action and identify potential therapeutic applications across a range of diseases. The outcomes of these trials are expected to contribute significantly to our understanding of this compound's role in modern medicine.

In conclusion, Filixic Acid ABA (CAS No. 38226-84-5) represents a fascinating example of how natural products can serve as sources for innovative drug discovery. Its unique structural features and diverse biological activities make it a compelling candidate for therapeutic development. As research continues to uncover new insights into its mechanisms of action, it is likely that Filixic Acid ABA will play an increasingly important role in addressing some of the most pressing challenges in human health.

• 12777-70-7(Dryocrassin ABBA)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)